Search

Displaying results 7341 - 7350 of 7673 in total
  1. Drug

    MBT-0312

    go.drugbank.com/drugs/DB05880
    Experimental

    MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.

  2. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).

  3. Drug

    Nicaraven

    go.drugbank.com/drugs/DB06397
    Experimental

  4. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.

  5. Drug

    INCB-9471

    go.drugbank.com/drugs/DB12960
    Investigational

    INCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.

  6. Drug

    Alicaforsen

    go.drugbank.com/drugs/DB06224
    Investigational

  7. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

  8. Drug

    Isatoribine

    go.drugbank.com/drugs/DB04860
    Experimental

    Isatoribine is a selective agonist of TLR7.

  9. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  10. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT0551...